Shares of Annovis Bio, Inc. (NYSE:ANVS – Get Free Report) have been assigned an average recommendation of “Buy” from the six analysts that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, four have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $33.60.
A number of equities research analysts have commented on the stock. EF Hutton Acquisition Co. I upgraded shares of Annovis Bio to a “strong-buy” rating in a report on Tuesday, August 13th. Canaccord Genuity Group reduced their price target on shares of Annovis Bio from $36.00 to $26.00 and set a “buy” rating for the company in a report on Tuesday, April 30th. Rodman & Renshaw restated a “buy” rating and issued a $67.00 price target on shares of Annovis Bio in a report on Tuesday, July 2nd. Finally, HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of Annovis Bio in a report on Thursday.
Get Our Latest Research Report on Annovis Bio
Institutional Inflows and Outflows
Annovis Bio Stock Down 3.6 %
Shares of NYSE ANVS opened at $8.53 on Wednesday. Annovis Bio has a twelve month low of $4.53 and a twelve month high of $22.49. The firm has a fifty day simple moving average of $8.81 and a 200 day simple moving average of $9.15. The company has a market capitalization of $95.29 million, a PE ratio of -1.48 and a beta of 1.74.
About Annovis Bio
Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.
Featured Articles
- Five stocks we like better than Annovis Bio
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- This Small Cap Wealth Management Stock Could Provide Big Returns
- What is a Death Cross in Stocks?
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- 5 discounted opportunities for dividend growth investors
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for Annovis Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annovis Bio and related companies with MarketBeat.com's FREE daily email newsletter.